Abivax is trading 4.16% lower at $87.91 as biotech-sector weakness weighs on shares.
- The provided sector context shows XBI down 2.50% during the session.
- No clear Abivax-specific announcement explaining the October 6 decline surfaced in the search.
- September first-half results and analyst target reductions are prior context, not evidence of a new catalyst today; the broader market is higher, making sector pressure the more relevant available explanation.